Cantor Fitzgerald reiterated their underweight rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a research note published on Tuesday morning. Cantor Fitzgerald currently has a $69.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $60.00.

“In AESOP, OCA-treated PSC patients demonstrated significant decrease from baseline in alkaline phosphatase (ALP) of -22% compared with placebo-treated patients’ increase of +1% at 24 weeks,” the firm said.”Additionally, CONTROL demonstrated atorvastatin’s ability to reduce elevations of LDL-C in OCA-treated patients by 40-48mg/dL.,” Cantor Fitzgerald’s analyst wrote.

A number of other research firms have also recently weighed in on ICPT. BidaskClub cut shares of Intercept Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, August 4th. Laidlaw reaffirmed a hold rating and set a $119.00 target price (up previously from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. BMO Capital Markets boosted their target price on shares of Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an outperform rating in a research note on Tuesday, August 1st. Finally, Wedbush reaffirmed a buy rating on shares of Intercept Pharmaceuticals in a research note on Monday, July 31st. Two analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $203.67.

Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded up 2.05% on Tuesday, reaching $103.19. The company’s stock had a trading volume of 343,264 shares. The company’s market cap is $2.59 billion. The firm has a 50 day moving average of $120.81 and a 200 day moving average of $117.78. Intercept Pharmaceuticals has a 52-week low of $96.63 and a 52-week high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same period in the previous year, the business earned ($3.14) earnings per share. The company’s revenue was up 459.6% on a year-over-year basis. Analysts predict that Intercept Pharmaceuticals will post ($14.05) earnings per share for the current year.

WARNING: “Cantor Fitzgerald Reiterates “Underweight” Rating for Intercept Pharmaceuticals, Inc. (ICPT)” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://theolympiareport.com/2017/08/12/cantor-fitzgerald-reiterates-underweight-rating-for-intercept-pharmaceuticals-inc-icpt.html.

In related news, Director Daniel G. Welch sold 217 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the sale, the director now owns 3,710 shares of the company’s stock, valued at $470,279.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Lisa Bright sold 254 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $117.52, for a total transaction of $29,850.08. Following the completion of the sale, the insider now directly owns 23,246 shares in the company, valued at approximately $2,731,869.92. The disclosure for this sale can be found here. In the last three months, insiders sold 47,575 shares of company stock worth $6,144,469. 9.20% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of ICPT. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. US Bancorp DE purchased a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $130,000. IFP Advisors Inc boosted its stake in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 730 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Intercept Pharmaceuticals during the first quarter worth approximately $170,000. Finally, Pacer Advisors Inc. boosted its stake in shares of Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares during the period. 83.93% of the stock is currently owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.